Amyris (NASDAQ:AMRS – Get Rating) announced its earnings results on Tuesday. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.07), Briefing.com reports. The business had revenue of $57.71 million for the quarter, compared to the consensus estimate of $65.45 million. During the same quarter in the prior year, the business posted ($1.08) earnings per share. The firm’s revenue for the quarter was down 67.4% on a year-over-year basis.
Shares of Amyris stock traded up $0.03 on Wednesday, hitting $1.76. 958,137 shares of the company traded hands, compared to its average volume of 5,507,079. The company has a 50-day moving average price of $4.15 and a 200 day moving average price of $5.64. The company has a quick ratio of 2.09, a current ratio of 2.37 and a debt-to-equity ratio of 1.26. Amyris has a 12-month low of $1.71 and a 12-month high of $17.42. The company has a market cap of $559.64 million, a PE ratio of -0.90 and a beta of 1.63.
AMRS has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 3rd. StockNews.com initiated coverage on shares of Amyris in a research note on Thursday, March 31st. They set a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $19.17.
About Amyris (Get Rating)
Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets.
- Get a free copy of the StockNews.com research report on Amyris (AMRS)
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
- Is Now The Time To Buy Coinbase (NASDAQ: COIN)?
- Inflation Hasn’t Peaked At Reynolds Consumer Products
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.